This title appears in the Scientific Report :
2019
Please use the identifier:
http://dx.doi.org/10.1039/C8MD00454D in citations.
Design, Synthesis and Biological Evaluation of β-Peptoid-Capped HDAC Inhibitors with Anti-Neuroblastoma and Anti-Glioblastoma Activity
Design, Synthesis and Biological Evaluation of β-Peptoid-Capped HDAC Inhibitors with Anti-Neuroblastoma and Anti-Glioblastoma Activity
Histone deacetylases (HDACs) have been identified as promising epigenetic drug targets for the treatment of neuroblastomaand glioblastoma. In this work, we have rationally designed a novel type of peptoid‐based histone deacetylase inhibitors(HDACi). A mini library of β‐peptoid‐capped HDACi was synth...
Saved in:
Personal Name(s): | Reßing, Nina |
---|---|
Marquardt, Viktoria / Gertzen, Christoph / Schöler, Andrea / Schramm, Alexander / Kurz, Thomas / Gohlke, Holger / Aigner, Achim / Remke, Marc / Hansen, Finn Kristian (Corresponding author) | |
Contributing Institute: |
John von Neumann - Institut für Computing; NIC Strukturbiochemie; ICS-6 Jülich Supercomputing Center; JSC |
Published in: | MedChemComm, 10 (2019) 7, S. 1109-1115 |
Imprint: |
Cambridge
RSC Publ.
2019
|
DOI: |
10.1039/C8MD00454D |
Document Type: |
Journal Article |
Research Program: |
Forschergruppe Gohlke Computational Science and Mathematical Methods |
Publikationsportal JuSER |
Histone deacetylases (HDACs) have been identified as promising epigenetic drug targets for the treatment of neuroblastomaand glioblastoma. In this work, we have rationally designed a novel type of peptoid‐based histone deacetylase inhibitors(HDACi). A mini library of β‐peptoid‐capped HDACi was synthesized using a four‐step protocol. All compounds were screenedin biochemical assays for its inhibition of HDAC1 and HDAC6 and docking studies were performed to rationalize the observedselectivity profile. The synthesized compounds were further examined for tumor cell‐inhibitory activity against a panel ofneuroblastoma and glioblastoma cell lines. In particular, non‐selective compounds with potent activity against HDAC1 andHDAC6 showed strong antiproliferative effects. The most promising HDACi, compound 6i, displayed submicromolar tumorcell‐inhibitory potential (IC50: 0.21 – 0.67 μM) against all five cancer cell lines investigated and exceeded the activity of theFDA‐approved HDACi vorinostat. |